Global Skin Neoplasms Market
Global Skin Neoplasms Market

Skin Neoplasms Comprehensive Study by Type (Benign Neoplasms (Skin Tags, Cherry Angioma, Dermatofibroma, Epidermoid Cyst, Keratoacanthoma, Lipoma, Pyogenic Granuloma, Sebaceous Hyperplasia, and Seborrheic Keratosis), Malignant Neoplasms (Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Kaposi Sarcoma, and Lymphoma of the Skin)), Treatment (Chemotherapy, Surgery, Non-Invasive Treatments, Others), End User (Hospital and Clinics, Diagnostic Centers, Cancer Research Institutes, Others) Players and Region - Global Market Outlook to 2025

Skin Neoplasms Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 221 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Skin Neoplasms Market Scope?
Skin neoplasm is an unusual growth on human skin. The word neoplasm is sometimes used interchangeably with cancer, but neoplasms can also be noncancerous. Increasing skin diseases is propelling the growth of the global skin neoplasm treatment market in the forecast period. World Health Organization predicts that around 2-3 million non-melanoma skin cancers and 1-1.5 million melanoma skin cancers cases are reported every year with one in three cancers diagnosed is skin cancer and one in five Americans develop skin cancer in their lifetime.

The Skin Neoplasms market study is being classified by Type (Benign Neoplasms (Skin Tags, Cherry Angioma, Dermatofibroma, Epidermoid Cyst, Keratoacanthoma, Lipoma, Pyogenic Granuloma, Sebaceous Hyperplasia, and Seborrheic Keratosis) and Malignant Neoplasms (Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Kaposi Sarcoma, and Lymphoma of the Skin)) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Companies are highly investing in R & D and are collaborating with other companies for developing products. Solaraze, Aldara, Erivedge, Carac are some of the major drugs for the treatment of skin neoplasms in the market.The Players having a strong hold in the market are F. Hoffmann-la Roche Ltd., Novartis International AG, Sun Pharma Industries Ltd., and Elekta AB. Research Analyst at AMA predicts that Players from United States will contribute to the maximum growth of Global Skin Neoplasms market throughout the predicted period.

F. Hoffmann-la Roche Ltd. (Switzerland), Novartis International AG (Switzerland), Sun Pharma Industries Ltd. (India), Elekta AB (Sweden), Varian Medical Systems Inc. (United States), Cannabis Science Inc. (United States), Cellceutix Corp. (United States), LEO Pharma A/S (Denmark), Moberg Pharma AB (Sweden), Mylan Pharmaceutical Inc. (United States), Oncothyreon Inc. (United States), Eli Lilly and Co. (United States), Bristol Myers Squibb Co. (United States) and Boehringer Ingelheim GmbH (Germany) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Aqua Pharmaceuticals LLC (united States), Valeant Pharmaceuticals Inc (Canada), Meda AB (US), iCAD Inc. (Sweden) and Merck & Co. Inc. (United States).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Skin Neoplasms market by Type, Application and Region.

On the basis of geography, the market of Skin Neoplasms has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

On 5th May 2020, Sanofi and Regeneron’s PD-1 inhibitor Libtayo in patients with advanced basal cell carcinoma (BCC) who had progressed on or were intolerant to prior hedgehog pathway inhibitor (HHI) therapy were announced.


Influencing Market Trend
  • Prevalence of Skin Cancer is Increasing Owing to Depleting Ozone Level

Market Drivers
  • Growing Incidents of Skin Cancers
  • Increasing Healthcare Spending in Developing Economies

Opportunities
  • Growing Technological Innovations for the Development of Drugs and Treatment

Restraints
  • Side Effects Associated with the Treatment

Challenges
  • Strict Regulation Regarding Drugs


Key Target Audience
Skin Neoplasms Drug Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.
Report Objectives / Segmentation Covered
By Type
  • Benign Neoplasms (Skin Tags, Cherry Angioma, Dermatofibroma, Epidermoid Cyst, Keratoacanthoma, Lipoma, Pyogenic Granuloma, Sebaceous Hyperplasia, and Seborrheic Keratosis)
  • Malignant Neoplasms (Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Kaposi Sarcoma, and Lymphoma of the Skin)
By Treatment
  • Chemotherapy
  • Surgery
  • Non-Invasive Treatments
  • Others

By End User
  • Hospital and Clinics
  • Diagnostic Centers
  • Cancer Research Institutes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Incidents of Skin Cancers
      • 3.2.2. Increasing Healthcare Spending in Developing Economies
    • 3.3. Market Challenges
      • 3.3.1. Strict Regulation Regarding Drugs
    • 3.4. Market Trends
      • 3.4.1. Prevalence of Skin Cancer is Increasing Owing to Depleting Ozone Level
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Skin Neoplasms, by Type, Treatment, End User and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Skin Neoplasms (Value)
      • 5.2.1. Global Skin Neoplasms by: Type (Value)
        • 5.2.1.1. Benign Neoplasms (Skin Tags, Cherry Angioma, Dermatofibroma, Epidermoid Cyst, Keratoacanthoma, Lipoma, Pyogenic Granuloma, Sebaceous Hyperplasia, and Seborrheic Keratosis)
        • 5.2.1.2. Malignant Neoplasms (Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Kaposi Sarcoma, and Lymphoma of the Skin)
      • 5.2.2. Global Skin Neoplasms by: Treatment (Value)
        • 5.2.2.1. Chemotherapy
        • 5.2.2.2. Surgery
        • 5.2.2.3. Non-Invasive Treatments
        • 5.2.2.4. Others
      • 5.2.3. Global Skin Neoplasms by: End User (Value)
        • 5.2.3.1. Hospital and Clinics
        • 5.2.3.2. Diagnostic Centers
        • 5.2.3.3. Cancer Research Institutes
        • 5.2.3.4. Others
      • 5.2.4. Global Skin Neoplasms Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Skin Neoplasms: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-la Roche Ltd. (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis International AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sun Pharma Industries Ltd. (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Elekta AB (Sweden)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Varian Medical Systems Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cannabis Science Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cellceutix Corp. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. LEO Pharma A/S (Denmark)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Moberg Pharma AB (Sweden)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mylan Pharmaceutical Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Oncothyreon Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Eli Lilly and Co. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Bristol Myers Squibb Co. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Boehringer Ingelheim GmbH (Germany)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
  • 7. Global Skin Neoplasms Sale, by Type, Treatment, End User and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Skin Neoplasms (Value)
      • 7.2.1. Global Skin Neoplasms by: Type (Value)
        • 7.2.1.1. Benign Neoplasms (Skin Tags, Cherry Angioma, Dermatofibroma, Epidermoid Cyst, Keratoacanthoma, Lipoma, Pyogenic Granuloma, Sebaceous Hyperplasia, and Seborrheic Keratosis)
        • 7.2.1.2. Malignant Neoplasms (Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Kaposi Sarcoma, and Lymphoma of the Skin)
      • 7.2.2. Global Skin Neoplasms by: Treatment (Value)
        • 7.2.2.1. Chemotherapy
        • 7.2.2.2. Surgery
        • 7.2.2.3. Non-Invasive Treatments
        • 7.2.2.4. Others
      • 7.2.3. Global Skin Neoplasms by: End User (Value)
        • 7.2.3.1. Hospital and Clinics
        • 7.2.3.2. Diagnostic Centers
        • 7.2.3.3. Cancer Research Institutes
        • 7.2.3.4. Others
      • 7.2.4. Global Skin Neoplasms Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Skin Neoplasms: by Type(USD Million)
  • Table 2. Skin Neoplasms Benign Neoplasms (Skin Tags, Cherry Angioma, Dermatofibroma, Epidermoid Cyst, Keratoacanthoma, Lipoma, Pyogenic Granuloma, Sebaceous Hyperplasia, and Seborrheic Keratosis) , by Region USD Million (2014-2019)
  • Table 3. Skin Neoplasms Malignant Neoplasms (Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Kaposi Sarcoma, and Lymphoma of the Skin) , by Region USD Million (2014-2019)
  • Table 4. Skin Neoplasms: by Treatment(USD Million)
  • Table 5. Skin Neoplasms Chemotherapy , by Region USD Million (2014-2019)
  • Table 6. Skin Neoplasms Surgery , by Region USD Million (2014-2019)
  • Table 7. Skin Neoplasms Non-Invasive Treatments , by Region USD Million (2014-2019)
  • Table 8. Skin Neoplasms Others , by Region USD Million (2014-2019)
  • Table 9. Skin Neoplasms: by End User(USD Million)
  • Table 10. Skin Neoplasms Hospital and Clinics , by Region USD Million (2014-2019)
  • Table 11. Skin Neoplasms Diagnostic Centers , by Region USD Million (2014-2019)
  • Table 12. Skin Neoplasms Cancer Research Institutes , by Region USD Million (2014-2019)
  • Table 13. Skin Neoplasms Others , by Region USD Million (2014-2019)
  • Table 14. South America Skin Neoplasms, by Country USD Million (2014-2019)
  • Table 15. South America Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 16. South America Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 17. South America Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 18. Brazil Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 19. Brazil Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 20. Brazil Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 21. Argentina Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 22. Argentina Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 23. Argentina Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 24. Rest of South America Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 25. Rest of South America Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 26. Rest of South America Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 27. Asia Pacific Skin Neoplasms, by Country USD Million (2014-2019)
  • Table 28. Asia Pacific Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 29. Asia Pacific Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 30. Asia Pacific Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 31. China Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 32. China Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 33. China Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 34. Japan Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 35. Japan Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 36. Japan Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 37. India Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 38. India Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 39. India Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 40. South Korea Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 41. South Korea Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 42. South Korea Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 43. Taiwan Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 44. Taiwan Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 45. Taiwan Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 46. Australia Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 47. Australia Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 48. Australia Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 49. Rest of Asia-Pacific Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 50. Rest of Asia-Pacific Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 51. Rest of Asia-Pacific Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 52. Europe Skin Neoplasms, by Country USD Million (2014-2019)
  • Table 53. Europe Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 54. Europe Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 55. Europe Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 56. Germany Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 57. Germany Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 58. Germany Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 59. France Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 60. France Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 61. France Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 62. Italy Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 63. Italy Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 64. Italy Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 65. United Kingdom Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 66. United Kingdom Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 67. United Kingdom Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 68. Netherlands Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 69. Netherlands Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 70. Netherlands Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 71. Rest of Europe Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 72. Rest of Europe Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 73. Rest of Europe Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 74. MEA Skin Neoplasms, by Country USD Million (2014-2019)
  • Table 75. MEA Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 76. MEA Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 77. MEA Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 78. Middle East Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 79. Middle East Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 80. Middle East Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 81. Africa Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 82. Africa Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 83. Africa Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 84. North America Skin Neoplasms, by Country USD Million (2014-2019)
  • Table 85. North America Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 86. North America Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 87. North America Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 88. United States Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 89. United States Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 90. United States Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 91. Canada Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 92. Canada Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 93. Canada Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 94. Mexico Skin Neoplasms, by Type USD Million (2014-2019)
  • Table 95. Mexico Skin Neoplasms, by Treatment USD Million (2014-2019)
  • Table 96. Mexico Skin Neoplasms, by End User USD Million (2014-2019)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Skin Neoplasms: by Type(USD Million)
  • Table 112. Skin Neoplasms Benign Neoplasms (Skin Tags, Cherry Angioma, Dermatofibroma, Epidermoid Cyst, Keratoacanthoma, Lipoma, Pyogenic Granuloma, Sebaceous Hyperplasia, and Seborrheic Keratosis) , by Region USD Million (2020-2025)
  • Table 113. Skin Neoplasms Malignant Neoplasms (Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Kaposi Sarcoma, and Lymphoma of the Skin) , by Region USD Million (2020-2025)
  • Table 114. Skin Neoplasms: by Treatment(USD Million)
  • Table 115. Skin Neoplasms Chemotherapy , by Region USD Million (2020-2025)
  • Table 116. Skin Neoplasms Surgery , by Region USD Million (2020-2025)
  • Table 117. Skin Neoplasms Non-Invasive Treatments , by Region USD Million (2020-2025)
  • Table 118. Skin Neoplasms Others , by Region USD Million (2020-2025)
  • Table 119. Skin Neoplasms: by End User(USD Million)
  • Table 120. Skin Neoplasms Hospital and Clinics , by Region USD Million (2020-2025)
  • Table 121. Skin Neoplasms Diagnostic Centers , by Region USD Million (2020-2025)
  • Table 122. Skin Neoplasms Cancer Research Institutes , by Region USD Million (2020-2025)
  • Table 123. Skin Neoplasms Others , by Region USD Million (2020-2025)
  • Table 124. South America Skin Neoplasms, by Country USD Million (2020-2025)
  • Table 125. South America Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 126. South America Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 127. South America Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 128. Brazil Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 129. Brazil Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 130. Brazil Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 131. Argentina Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 132. Argentina Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 133. Argentina Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 134. Rest of South America Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 135. Rest of South America Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 136. Rest of South America Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 137. Asia Pacific Skin Neoplasms, by Country USD Million (2020-2025)
  • Table 138. Asia Pacific Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 139. Asia Pacific Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 140. Asia Pacific Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 141. China Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 142. China Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 143. China Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 144. Japan Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 145. Japan Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 146. Japan Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 147. India Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 148. India Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 149. India Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 150. South Korea Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 151. South Korea Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 152. South Korea Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 153. Taiwan Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 154. Taiwan Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 155. Taiwan Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 156. Australia Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 157. Australia Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 158. Australia Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 159. Rest of Asia-Pacific Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 160. Rest of Asia-Pacific Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 161. Rest of Asia-Pacific Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 162. Europe Skin Neoplasms, by Country USD Million (2020-2025)
  • Table 163. Europe Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 164. Europe Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 165. Europe Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 166. Germany Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 167. Germany Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 168. Germany Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 169. France Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 170. France Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 171. France Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 172. Italy Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 173. Italy Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 174. Italy Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 175. United Kingdom Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 176. United Kingdom Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 177. United Kingdom Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 178. Netherlands Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 179. Netherlands Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 180. Netherlands Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 181. Rest of Europe Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 182. Rest of Europe Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 183. Rest of Europe Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 184. MEA Skin Neoplasms, by Country USD Million (2020-2025)
  • Table 185. MEA Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 186. MEA Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 187. MEA Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 188. Middle East Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 189. Middle East Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 190. Middle East Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 191. Africa Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 192. Africa Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 193. Africa Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 194. North America Skin Neoplasms, by Country USD Million (2020-2025)
  • Table 195. North America Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 196. North America Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 197. North America Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 198. United States Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 199. United States Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 200. United States Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 201. Canada Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 202. Canada Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 203. Canada Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 204. Mexico Skin Neoplasms, by Type USD Million (2020-2025)
  • Table 205. Mexico Skin Neoplasms, by Treatment USD Million (2020-2025)
  • Table 206. Mexico Skin Neoplasms, by End User USD Million (2020-2025)
  • Table 207. Research Programs/Design for This Report
  • Table 208. Key Data Information from Secondary Sources
  • Table 209. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Skin Neoplasms: by Type USD Million (2014-2019)
  • Figure 5. Global Skin Neoplasms: by Treatment USD Million (2014-2019)
  • Figure 6. Global Skin Neoplasms: by End User USD Million (2014-2019)
  • Figure 7. South America Skin Neoplasms Share (%), by Country
  • Figure 8. Asia Pacific Skin Neoplasms Share (%), by Country
  • Figure 9. Europe Skin Neoplasms Share (%), by Country
  • Figure 10. MEA Skin Neoplasms Share (%), by Country
  • Figure 11. North America Skin Neoplasms Share (%), by Country
  • Figure 12. Global Skin Neoplasms share by Players 2019 (%)
  • Figure 13. Global Skin Neoplasms share by Players (Top 3) 2019(%)
  • Figure 14. Global Skin Neoplasms share by Players (Top 5) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. F. Hoffmann-la Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. F. Hoffmann-la Roche Ltd. (Switzerland) Revenue: by Geography 2019
  • Figure 18. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis International AG (Switzerland) Revenue: by Geography 2019
  • Figure 20. Sun Pharma Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 21. Sun Pharma Industries Ltd. (India) Revenue: by Geography 2019
  • Figure 22. Elekta AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 23. Elekta AB (Sweden) Revenue: by Geography 2019
  • Figure 24. Varian Medical Systems Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Varian Medical Systems Inc. (United States) Revenue: by Geography 2019
  • Figure 26. Cannabis Science Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Cannabis Science Inc. (United States) Revenue: by Geography 2019
  • Figure 28. Cellceutix Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Cellceutix Corp. (United States) Revenue: by Geography 2019
  • Figure 30. LEO Pharma A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 31. LEO Pharma A/S (Denmark) Revenue: by Geography 2019
  • Figure 32. Moberg Pharma AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 33. Moberg Pharma AB (Sweden) Revenue: by Geography 2019
  • Figure 34. Mylan Pharmaceutical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Mylan Pharmaceutical Inc. (United States) Revenue: by Geography 2019
  • Figure 36. Oncothyreon Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Oncothyreon Inc. (United States) Revenue: by Geography 2019
  • Figure 38. Eli Lilly and Co. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Eli Lilly and Co. (United States) Revenue: by Geography 2019
  • Figure 40. Bristol Myers Squibb Co. (United States) Revenue, Net Income and Gross profit
  • Figure 41. Bristol Myers Squibb Co. (United States) Revenue: by Geography 2019
  • Figure 42. Boehringer Ingelheim GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 43. Boehringer Ingelheim GmbH (Germany) Revenue: by Geography 2019
  • Figure 44. Global Skin Neoplasms: by Type USD Million (2020-2025)
  • Figure 45. Global Skin Neoplasms: by Treatment USD Million (2020-2025)
  • Figure 46. Global Skin Neoplasms: by End User USD Million (2020-2025)
  • Figure 47. South America Skin Neoplasms Share (%), by Country
  • Figure 48. Asia Pacific Skin Neoplasms Share (%), by Country
  • Figure 49. Europe Skin Neoplasms Share (%), by Country
  • Figure 50. MEA Skin Neoplasms Share (%), by Country
  • Figure 51. North America Skin Neoplasms Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • F. Hoffmann-la Roche Ltd. (Switzerland)
  • Novartis International AG (Switzerland)
  • Sun Pharma Industries Ltd. (India)
  • Elekta AB (Sweden)
  • Varian Medical Systems Inc. (United States)
  • Cannabis Science Inc. (United States)
  • Cellceutix Corp. (United States)
  • LEO Pharma A/S (Denmark)
  • Moberg Pharma AB (Sweden)
  • Mylan Pharmaceutical Inc. (United States)
  • Oncothyreon Inc. (United States)
  • Eli Lilly and Co. (United States)
  • Bristol Myers Squibb Co. (United States)
  • Boehringer Ingelheim GmbH (Germany)
Additional players considered in the study are as follows:
Aqua Pharmaceuticals LLC (united States) , Valeant Pharmaceuticals Inc (Canada) , Meda AB (US), iCAD Inc. (Sweden) , Merck & Co. Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation